This document summarizes a case study involving a 19-year old male (EG) who was admitted to the ICU following a high-speed motorcycle accident and subsequent traumatic brain injury. EG remains intubated and sedated, with elevated heart rate, temperatures, and signs of sympathetic hyperactivity. The attending physician asks the clinical pharmacist about evidence for using propranolol to treat EG's sympathetic hyperactivity. The pharmacist then reviews the pathophysiology and presentation of paroxysmal sympathetic hyperactivity, current treatment options including beta blockers like propranolol, and a literature review on the use of beta blockers including propranolol in traumatic brain injury patients.
This is a PDF of a presentation given to the Radiation Oncology department at the University of Minnesota in October 2015. This PDF focuses on evaluation, management, and state-of-the-art approach to gliomas from a medical neuro-oncology perspective.
This is a PDF of a presentation given to the Radiation Oncology department at the University of Minnesota in October 2015. This PDF focuses on evaluation, management, and state-of-the-art approach to gliomas from a medical neuro-oncology perspective.
Genetic Scoring Related to Renal Denervation ResponseScottSnyder78
Multi-Organ Genetic Scoring is Related to the Response to Renal Denervation in Patients With Hypertension.
Geneticure genotyped subjects from the Medtronic OFF-MED renal denervation trial to assess the relationship between the genetic scoring (in which patients with a high score were hypothesized to be greater responders) and 24hour blood pressure changes from baseline to three months. There was a significant relationship between the Geneticure score and response to renal denervation. When divided into a median split of the Geneticure score, those with a high responder score had a ~14mmHg drop in blood pressure and those with a low score had no change in blood pressure, a statistically significant difference (p<0.001). When dividing the patients into tertiles, the highest tertile demonstrated a drop in blood pressure of ~13mmHg, the middle tertile a drop of ~6mmHg, and the low tertile an increase in BP of ~5mmHg.
The importance of sex and gender in medical researchCoda Change
The importance of sex and gender in medical research.
For many years it was widely assumed that the occurrence and outcome of disease was the same for women and men.
Our understanding was that studies involving only men would be equally relevant for women. In the last two decades however, it has been shown that this assumption is highly prejudice and can have a detrimental impact on the health of women.
It is, therefore, really important to incorporate a sex and gender research lens in to medical research.
First, Kelly makes the important distinction between sex and gender and how this can impact medical diagnosis, treatment and outcomes.
Then, she identifies how the incorporation of sex and gender into research has allowed for advancements across healthcare. Improved accuracy, avoiding misinterpretation, reduced unintentional bias and greater social equity to name a few.
In this presentation, Kelly Thompson refers to case studies to examine the differences in the interpretation of health data when examining through a sex and gender research lens.
The severity of disease, risk factors and treatment effectiveness are just a few of the reasons why this is so important.
Kelly encourages researchers to ensure gender diversity in the research team and to explain how sex and gender are accounted for in research applications moving forward.
From CodaZero Live, tune into this fascinating discussion on the importance of sex and gender in medical research by Kelly Thompson.
Don't miss our upcoming webinars. Subscribe today!
This presentation will highlight the promising new therapeutic strategies in the treatment of gliomas, with a focus on trials or therapies that will soon be available for Canadian patients.
View the YouTube video: https://youtu.be/ibbEuvSF7xY
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Neuroimaging Mastery Project Presentation #4: Acute Epidural HematomasSean M. Fox
Drs. Faith Meyers, Madison Watts and Steven Perry are Emergency Medicine Residents at Carolinas Medical Center who are interested in medical education. Along with the guidance of Dr. Michael Gibbs (Chair of Emergency Medicine), Dr. Jonathan Clemente (Chief of the Department of Radiology and Neuroradiology specialist), Dr. Christa Swisher (Neurocritcal Care Intensivist), and Dr. Scott Wait (Chief of Pediatric Neurosurgery) they aim to help educate us on Neuroimaging. In this presentation they will address Atraumatic Neurosurgical Intracranial Infections. Follow along with the EMGuideWire.com team as they post the CMC Neuroimaging Case Studies.
- Acute Epidural Hematomas
Audio and slides for this presentation are available on YouTube: http://youtu.be/6W_xoH4s-Yk
Dr. Patrick Wen, of Dana-Farber Cancer Institute's Center for Neuro-Oncology, discusses current clinical trial options for brain tumor patients and some of the new therapies available in neuro-oncology. This presentation was originally given at Dana-Farber Cancer Institute on Dec. 4, 2013.
Genetic Scoring Related to Renal Denervation ResponseScottSnyder78
Multi-Organ Genetic Scoring is Related to the Response to Renal Denervation in Patients With Hypertension.
Geneticure genotyped subjects from the Medtronic OFF-MED renal denervation trial to assess the relationship between the genetic scoring (in which patients with a high score were hypothesized to be greater responders) and 24hour blood pressure changes from baseline to three months. There was a significant relationship between the Geneticure score and response to renal denervation. When divided into a median split of the Geneticure score, those with a high responder score had a ~14mmHg drop in blood pressure and those with a low score had no change in blood pressure, a statistically significant difference (p<0.001). When dividing the patients into tertiles, the highest tertile demonstrated a drop in blood pressure of ~13mmHg, the middle tertile a drop of ~6mmHg, and the low tertile an increase in BP of ~5mmHg.
The importance of sex and gender in medical researchCoda Change
The importance of sex and gender in medical research.
For many years it was widely assumed that the occurrence and outcome of disease was the same for women and men.
Our understanding was that studies involving only men would be equally relevant for women. In the last two decades however, it has been shown that this assumption is highly prejudice and can have a detrimental impact on the health of women.
It is, therefore, really important to incorporate a sex and gender research lens in to medical research.
First, Kelly makes the important distinction between sex and gender and how this can impact medical diagnosis, treatment and outcomes.
Then, she identifies how the incorporation of sex and gender into research has allowed for advancements across healthcare. Improved accuracy, avoiding misinterpretation, reduced unintentional bias and greater social equity to name a few.
In this presentation, Kelly Thompson refers to case studies to examine the differences in the interpretation of health data when examining through a sex and gender research lens.
The severity of disease, risk factors and treatment effectiveness are just a few of the reasons why this is so important.
Kelly encourages researchers to ensure gender diversity in the research team and to explain how sex and gender are accounted for in research applications moving forward.
From CodaZero Live, tune into this fascinating discussion on the importance of sex and gender in medical research by Kelly Thompson.
Don't miss our upcoming webinars. Subscribe today!
This presentation will highlight the promising new therapeutic strategies in the treatment of gliomas, with a focus on trials or therapies that will soon be available for Canadian patients.
View the YouTube video: https://youtu.be/ibbEuvSF7xY
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Neuroimaging Mastery Project Presentation #4: Acute Epidural HematomasSean M. Fox
Drs. Faith Meyers, Madison Watts and Steven Perry are Emergency Medicine Residents at Carolinas Medical Center who are interested in medical education. Along with the guidance of Dr. Michael Gibbs (Chair of Emergency Medicine), Dr. Jonathan Clemente (Chief of the Department of Radiology and Neuroradiology specialist), Dr. Christa Swisher (Neurocritcal Care Intensivist), and Dr. Scott Wait (Chief of Pediatric Neurosurgery) they aim to help educate us on Neuroimaging. In this presentation they will address Atraumatic Neurosurgical Intracranial Infections. Follow along with the EMGuideWire.com team as they post the CMC Neuroimaging Case Studies.
- Acute Epidural Hematomas
Audio and slides for this presentation are available on YouTube: http://youtu.be/6W_xoH4s-Yk
Dr. Patrick Wen, of Dana-Farber Cancer Institute's Center for Neuro-Oncology, discusses current clinical trial options for brain tumor patients and some of the new therapies available in neuro-oncology. This presentation was originally given at Dana-Farber Cancer Institute on Dec. 4, 2013.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
1. Investigating the Role of Propranolol
in Paroxysmal Sympathetic
Hyperactivity
Anna Sandler, PharmD Candidate, 2023
1
2. Learning Objectives
Explain the epidemiology, pathophysiology, and
clinical features of paroxysmal sympathetic
hyperactivity.
Recognize current treatments for paroxysmal
sympathetic hyperactivity.
Synthesize available evidence to determine place in
therapy of propranolol.
Apply findings for a patient case.
2
3. Patient case
EG is a 19 year-old male with no significant past medical history who is
brought to Lutheran General Hospital (LGH) with multiple fractures and a
head injury after a high-speed motorcycle accident. Imaging revealed
intraparenchymal, ventricular and subdural hemorrhages on the left side as
well as multiple fractures. The patient underwent immediate interventions
and was admitted to the surgical intensive care unit (SICU).
Imaging
Initial
Interventions
• Seizing upon
arrival
• Hypotensive
• GCS: 5
Physical
Exam/Vitals
3
07.12-15.2022 07.28-29.2022 Future?
• Multiple
hemorrhages
• Scapular,
tibial, fibular
and sacral
fractures
• Intubation
• External
fixation of
tibial/fibular
fractures
• EVD
placement
4. Patient case-continued
07.12-15.2022 07.28-29.2022 Future?
EG remains intubated and sedated. His medication regimen has changed
due to seizure activity, high heart rate (HR) and elevated temperatures.
Indication Medication Notes
Neuro
management
Levetiracetam
Hydralazine
0.9% NaCl and 3%
NaCl
Levetiracetam: 750 mg BID, Increased from 500
mg BID due to EEG activity
Hydralazine PRN for systolic BP < 140 mmHg
0.9% NaCl continuous infusion
3% NaCl PRN low Na goals
Analgo-
sedation
Fentanyl, propofol Titrated to goal pain/sedation levels
Infection Vancomycin and
Meropenem
Discontinuing with culture results
Sputum grew methicillin- susceptible
Staphylococcus aureus (MSSA)
Prophylaxis Enoxaparin 30 mg SubQ BID
Elevated HR
and temps
Gabapentin
Propranolol
Propranolol increased to 50 mg QID
5. 07.12-15.2022 07.28-29.2022 Future?
Clinical Question
During rounds, a medical resident asks whether EG’s
antibiotics need to be changed due to his persistent elevated
temperatures. The attending explains this is most likely due
to sympathetic hyperactivity and asks you about
propranolol.
What is the evidence behind propranolol in sympathetic
hyperactivity?
6. Background Lit. Review Back to EG Future studies
Zheng RZ, et al. Front Neurol. 2020;11:81. doi:10.3389/fneur.2020.00081. Accessed August 9, 2022
https://www.ems1.com/traumatic-brain-injury/articles/quick-take-risk-factors-and-interventions-for-patients-with-
tbi-OXdT3hiYO8DN9iTf/, accessed August 7, 2022
Sakai, K.,. Egypt J Neurosurg 37, 7 (2022). Accessed August 9, 2022
6
Paroxysmal Sympathetic Hyperactivity
(PSH)
• Disordered regulation of the autonomic
system.
• Most commonly after severe traumatic
brain injury (TBI)-worse outcomes in
deeper injuries (parenchyma, brainstem).
• Variable incidence rate (8-33%)
• Associated with worse outcomes secondary
to complications, under-recognition, and
misdiagnosis.
More common in
males and
younger patients
7. Background Lit. Review Back to EG Future studies
Baguley IJ. Med Hypotheses. 2008;70(1):26-35. Accessed Aug 9, 2022
Zheng RZ, et al. Front Neurol. 2020;11:81. Accessed Aug 9, 2022
7
Pathophysiology
• Several theories exist
• Excitatory/inhibitory ratio
(EIR) theory
• Inhibition of descending
and afferent non-noxious
feedback impaired
TBI
Normal PSH
SEI
BEI
BEI
SEI
Non-
noxious
stimuli
Non-
noxious
stimuli
Non-
painful
Painful
Loss of
inhibition
8. Background Lit. Review Back to EG Future studies
8
Pathophysiology
• Neuroendocrine perspective:
Uncontrollable adrenergic
outflow
• Increased norepinephrine
(NE), dopamine (D),
epinephrine (E) and
adrenocorticotropic hormone
(ACTH)
TBI
Normal PSH
NE
E
D NE
NE
E
E
D
D
Zheng RZ, et al. Front Neurol. 2020;11:81. Accessed Aug 9, 2022
9. Clinical Presentation
• Tachycardia and hypertension
• Tachypnea: respiratory alkalosis
Cardio/pulmonary
• Diaphoresis Dehydration
• Hyperthermia
Temperature
• Rapid onset, duration varies, untreated: 20-30 minutes
• Triggers: ET suctioning, loud noises, repositioning
Episode course
9
UpToDate. https://www.uptodate.com/contents/paroxysmal-sympathetic-
hyperactivity#H395247466. Accessed August 9, 2022
Background Lit. Review Back to EG Future studies
10. • Based on clinical
symptoms+ diagnosis of
exclusion
• PSH Assessment Measure
(PSHam)
• Clinical Feature Scale+
Diagnosis Likelihood Tool
(DLT)
10
Background Lit. Review Back to EG Future studies
Diagnosis
PSHam
CFS
HR, RR, SBP,
Temp,
Sweating,
Posturing
DLT
Paroxysmal,
temporal
features,
response to
medications
UpToDate. https://www.uptodate.com/contents/paroxysmal-sympathetic-
<8= PSH unlikely
8-16= PSH possible
≥17 = PSH probable
11. 11
Knowledge Check
• What are EG’s risk factors for developing PSH?
• What clinical features does EG present with on 7/28-7/29 that
are consistent with PSH?
• What are some differentials that could lead to misdiagnosis of
PSH?
Background Lit. Review Back to EG Future studies
13. 13
Background Lit. Review Back to EG Future studies
Current Treatment
•Reducing stimulation
•Physiotherapy
•Sedation
•Room temperature control
Supportive Care
•Clonidine
•Beta Blockers
•Morphine
•Gabapentin
Pharmacologic therapy
Adjuncts:
Bromocriptine,
baclofen,
benzodiazepines
Zheng RZ, et al. Front Neurol. 2020;11:81. Accessed Aug 9, 2022
14. • Non-selective
beta blocker
decreases HR,
myocardial
contractility, BP
• Reduces cerebral
blood flow and
oxygen
consumption
Class/MOA Indications
14
Background Lit. Review Back to EG Future studies
Propranolol
• Arrhythmias
• Migraine
prophylaxis
• Thyroid storm
• Performance
anxiety disorder
No propranolol Propranolol
UpToDate. https://www.uptodate.com/contents/propranolol-drug-
information?search=propranolol&source=panel_search_result&selectedTitle=1~150&usage_
type=panel&kp_tab=drug_general&display_rank=1#F214884. Accessed Aug 10, 2022
15. Pharmacokinetics Adverse Reactions
• PHS starting dose:
10 mg TID
Dosing/Administration
15
• Onset: 1-2 hours
after PO
• Rapid and
Complete PO
absorption, F~ 0.25
• 4 L/kg distribution
• IR t1/2: 3-6 hrs; ER
8-10 hrs
• Highly lipophilic
• CNS
penetration
Background Lit. Review Back to EG Future studies
Propranolol
• Common
• Diarrhea,
vomiting
• Dizziness, fatigue
• Serious
• Brady-
arrhythmias
• Heart failure,
Heart block,
hypotension
• Bronchospasms
16. 16
Background Lit. Review Back to EG Future studies
Proposed Benefits of Propranolol
Neuro-
protective
Mitigates
hyper
adrenergic
state
Optimizes
brain
perfusion
Brain
volume
control
Mitigates
vasogenic
edema
Koskinen LOD, et al. 2014. Neuroscience 283:245-255. Accessed Aug 12, 2022
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
17. Background Lit. review Back to EG Future Studies
Literature Review:
17
Beta Blockers in Critically Ill Patients with
Traumatic Brain Injury: Results from a
Multi-Center, Prospective, Observational
AAST Study
Eric J. Ley, MD; Samuel D. Leonard, BS, Galinos
Barmparas, MD et al. 2018
18. 18
•Evaluate the effects of beta blockers (BBs) on mortality in
TBI patients
Objective
•Multi-center, prospective, observational trial
Design
• Compared patients receiving any BB during admission to
those who did not (BB-)
Intervention
Background Lit. review Back to EG Future Studies
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
19. Inclusion Criteria
Exclusion Criteria
19
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
Background Lit. review Back to EG Future Studies
• >/= 18 y/o
• Blunt TBI w/ CT demonstrating acute TBI
• ICU admission at presentation
• Expired patients in the ED
• > 12 hours since injury if transferring from
outside hospital
20. 20
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
Background Lit. review Back to EG Future Studies
Data Collection
• Enrolled adult trauma patients with a TBI requiring ICU admission
from January 1, 2015 to January 31, 2017
• Data for patients meeting inclusion criteria collected
• Age, gender
• Mechanism of injury
• Glasgow Comas Scale (GCS) score
• CT head findings and hospital procedures
• Systolic Blood pressure
• Other medications
• Abbreviated Injury Scale (AIS) score and Injury Severity Score
(ISS)
• Beta blocker indication: PSH, HTN, Tachycardia, etc.
21. Brown PA, et al. JAMA. 2021;325(9):833. doi:10.1001/jama.2021.0669
10%
mortality
rate
2l65
patients 90% power 2% difference
21
Outcomes Statistical Test
• 30-day
mortality
• Length of
hospital stay
• Student’s t test or Mann-Whitney U-Test
• Chi-Square or Fischer’s exact test
• Multivariate logistic regression model+ adjusted
odds ratios (AORs) and 95% CIs
• Kaplan-Meier (KM) curves with Cox-regression
model with adjusted hazard ratios (AHR) and 95%
CIs
• P < 0.05
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
Background Lit. review Back to EG Future Studies
22. Results-Baseline Characteristics
Characteristic BB (1120) BB- (1132) P-value
Most
common
BB:
labetalol
IV,
propra-
nolol PO
3rd most
common
Age (mean years) 57 49 < 0.01
Male (%) 70 68 0.29
MVC (%) 21 24 < 0.01
Fall (%) 43 35 <0.01
anticoagulant (%) 24 13 < 0.01
Pre-hospital BB (%) 17 1 < 0.01
GCS </=8 (%) 40 36 0.09
ISS <16 18 34 <0.01
ISS 16-25 36 38 < 0.01
ISS > 25 46 28 < 0.01
SAH 67 60 0.02
IPH 27 25 0.31
22
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
Background Lit. review Back to EG Future Studies
23. Results: 30-day mortality
Endpoint BB (n=1120) BB- (n=1132) AOR (95% CI)
30-day
mortality
13.8% 17.7% 0.35 (0.26-
0.47), adjusted
p <0.001
23
Background Lit. review Back to EG Future Studies
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
Endpoint BB (n=1120) BB- (n=1132) AHR (95% CI)
Adjusted 30-
day mortality
0.42 (0.33-
0.53), adjusted
p < 0.001
NNT
~26
24. Results: Length of stay
Endpoint BB (n=1120) BB- (n=1132) Adjusted mean
difference (95% CI)
Overall
hospital stay
(mean days +/-
SD)
21 +/- 25 10 +/- 37 8.00 (4.82-11.15);
adjusted p-value <
0.01
24
Background Lit. review Back to EG Future Studies
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
25. Results: Lower mortality in propranolol cohort
Endpoint Propranolol
(n=354)
Other BB (n=766) AOR (95% CI)
30-day
mortality
9.3% 15.9% 0.51 (0.31-0.85),
adjusted p =.010
25
Background Lit. review Back to EG Future Studies
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
NNT ~15
26. Conclusions
26
Survival
MOA
Non-
randomized
Researchers
• Patients who received beta
blockers after TBI had a lower
unadjusted and adjusted
mortality rate even after
accounting for survival bias
• Propranolol associated with lower
mortality rate than other BBs
Need for randomized controlled studies
Background Lit. review Back to EG Future Studies
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
27. Strengths and Weaknesses
27
• Generated KM curves to
account for survival bias
and effect of BB timing
administration
• Profile similar to patient
EG
• Multi-center and large
number of patients
Ley EJ et al. 2018 J Trauma Acute Care Surg. 2018 Feb;84(2):234-244. Accessed
Background Lit. review Back to EG Future Studies
• Observational trial
• Potential for different
results with propensity-
score matching
• Selection bias with
earlier deaths
• Unequal baseline
characteristics
• Lack of long-term follow
up
28. Background Lit. review Back to EG Future Studies
Literature Review:
28
Role of Early Propranolol in Weaning from
Mechanical Ventilator in Severe Traumatic
Brain Injury Patients
Tamer Habib, Ahmed Sabry, Ahmed El-Beheiry,
Islam Ahmed
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
29. 29
•Investigate whether early, low-dose propranolol after severe
TBI (EPAT) can affect weaning from mechanical
ventilation (MV).
Objective
•Prospective randomized trial conducted in Egypt
Design
• Propranolol 40 mg PO BID (EPAT) versus no BB use (no
EPAT)
• Administered within 24 hours from admission
Intervention
Background Lit. review Back to EG Future Studies
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
30. 30
Primary Outcome Statistical Test
• Number of days on a MV
Background Lit. review Back to EG Future Studies
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
• Mann-Whitney U-Test
• Chi-Square or Fischer’s exact test
• P < 0.05
31. Results-Baseline Characteristics
Characteristic EPAT (n= 102) Non-EPAT (n-238) P-value
Age (years) 23-64 24-60 0.061
GSC (mean) 5.12 5.99 0.001
Head AIS score (mean) 3.17 3.64 0.0031
ISS (mean) 17.65 19.74 0.001
SBP (mmHg) (mean) 139.4 140.18 0.579
HR (beats min) (mean) 96.36 87.29 0.0021
Subdural hematoma (%) 31.4 32.8 0.692
Intraventricular
hemorrhage (%)
12.7 9.7 0.822
No significant differences between receipt of mannitol, 3% NaCl,
Craniotomy/craniectomy, or type of brain injury
31
Background Lit. review Back to EG Future Studies
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
32. Results: Efficacy
32
Background Lit. review Back to EG Future Studies
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
Endpoint EPAT (n=102) Non-EPAT
(n=238)
P
Duration of
ventilation (range
days)
4-12 6-16 0.0013
ICU length of stay
(range days)
6-16 8-20 0.003
Hospital stay (range
days)
8-20 10-24 0.005
Mortality [n (%)] 55 (53.92) 125 (52.52) 0.392
33. Results: Safety and Complications
33
Background Lit. review Back to EG Future Studies
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
Endpoint EPAT (n=102) Non-EPAT
(n=238)
P
Bradycardia events
(mean)
1.7 4.8 0.06
Hypotensive events
(mean)
0.9 0.7 0.50
ARDS [n (%)] 4 (3.92) 6 (2.52) 0.70
VAP [n (%)] 10 (9.80 20 (8.40) 0.70
DVT [ (n (%)] 1 (0.98) 2 (0.84) 0.09
34. Conclusions
34
Large studies + mortality
Safety
Length
of stay
MV
duration
Researchers
• EPAT does not increase number or
severity of hypotensive episodes
• EPAT after TBI may be associated with
decreased MV duration and ICU length
of stay
• EPAT does not decrease mortality in the
ICU
Background Lit. review Back to EG Future Studies
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
35. Strengths and Weaknesses
35
Habib, TN et al. 2018 Research and Opinion in Anesthesia and Intensive Care 5.1: 15. Accessed
Background Lit. review Back to EG Future Studies
• Single center and small
sample sizes study limit
conclusions
• Randomized study
• Baseline
characteristics well
balanced
• Good representation
of EG’s head injuries
and closest age range
to EG
36. Background Lit. review Back to EG Future Studies
Literature Review:
36
Using Propranolol in Traumatic Brain
Injury to Reduce Sympathetic Storm
Phenomenon: A Prospective Randomized
Clinical Trial
Mona Ahmed Ammar, Noha Sayed Husein
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
37. 37
•Evaluate the effects of propranolol on catecholamine levels
and vitals/labs
Objective
•Single-center, randomized, double-blinded, placebo-
controlled trial
Design
• Propranolol 1mg IV versus IV placebo
Intervention
Background Lit. review Back to EG Future Studies
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
38. Inclusion Criteria
Exclusion Criteria
38
Background Lit. review Back to EG Future Studies
• Isolated blunt TBI
• 18-60 years old
• GCS 9-12 and normal procalcitonin
• Pre-existing heart disease, MI, craniotomy, pre-
existing cerebral dysfunction, spinal cord injury,
DM, sepsis, severe liver or kidney disease
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
39. 39
Background Lit. review Back to EG Future Studies
Intervention and Monitoring
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
• Group B: IV placebo same timeline as group A
• Group A: IV propranolol 1 mg every 6 hours from
admission- for 7 days
• Doses stopped for HR < 60 BPM, MAP < 60 mmHg
Monitoring: Vitals every 2 hours (HR, RR, MAP,
temp), catecholamine levels on admission and day 7
40. 40
Outcomes Statistical Test
• Catecholamine
levels
• Vitals and Labs
Background Lit. review Back to EG Future Studies
• Chi-square tests
• Independent t-test
• Mann-Whitney Test
• P < 0.05
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
41. Results-Baseline Characteristics
Characteristic Group A (n=30) Group B (n=30) P-value
Age (years) 52 +/- 11.66 55 +/- 12.3 0.238
Sex (male: female) 18:12 16:14 0.602
41
Background Lit. review Back to EG Future Studies
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
• No statistical differences between the two
groups
• Overall age range: 18-65 years old
42. Results: Efficacy
42
Background Lit. review Back to EG Future Studies
Endpoint Group A
(n=30)
Group B (n=30) P
NE (pg/mL) day 1 (mean) 523.50 548.00 0.035
NE (pg/mL) day 7 (mean) 206.87 529.33 < 0.001
E (pg/mL) day 1 (mean) 205.37 194.53 0.121
E(pg/mL) day 7 (mean) 69.00 190.73 < 0.001
D(pg/mL) day 1 (mean) 81.63 80.13 0.477
D(pg/mL) day 7 (mean) 32.90 78.00 < 0.001
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
43. 43
Background Lit. review Back to EG Future Studies
Endpoint Group A
(n=30)
Group B (n=30) P
MABP day 1 (mean) 109.70 109.47 0.896
MABP day 7 (mean) 80.83 90.10 < 0.001
HR day 1 (beats/min,
mean)
106.2 107.00 0.690
HR day 7 (beats/min,
mean)
69.53 90.00 < 0.001
RR day 1 27.73 26.33 0.182
RR day 7 16.03 18.20 < 0.001
Temp day 1 (deg. C) 38.68 38.36 0.065
Temp day 7 (deg. C) 37.16 38.25 < 0.001
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
44. Conclusions
44
Support early use of
propranolol
GCS
outcomes
Lower E,
NE, D
levels
Improved
HR, RR,
temp
Researchers
• Propranolol reduced manifestations of
sympathetic storm, with better control of
temperature
Background Lit. review Back to EG Future Studies
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
45. Strengths and Weaknesses
45
Background Lit. review Back to EG Future Studies
• Single center study
• Small number of participants
• Exclusion of GCS </= 8 and
many disease states to favor
an overall healthier
population
• Lack of long-term outcomes
• Randomized study
• Similar baseline
characteristics w/
few sig. differences
on day 1
Ammar MA, et al. 2018. Saudi J Anaesth. 2018 Oct-Dec;12(4):514-520. Accessed Aug 11, 2022
46. Background Lit. review Back to EG Future Studies
Literature Review:
46
Beta-Blocker Therapy In Severe Traumatic
Brain Injury: A Prospective Randomized
Controlled Trial
Hosseinali Khalil, Rebccka Ahl, Shhram Paydar,
et al. 2020
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
47. 47
•Examine effect of BBs on outcomes in severe intracranial
TBI patients
Objective
•Single-center, non-blinded randomized trial
Design
• Propranolol 20 mg PO Q12H versus placebo
Intervention
Background Lit. review Back to EG Future Studies
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
48. Inclusion Criteria
Exclusion Criteria
48
Background Lit. review Back to EG Future Studies
• AIS >/= 3 (severe intracranial injury)
• >/= 18 y/o
• NICU admission
• Pre-existing beta blocker therapy
• Persistent shock (SBP < 100 mmHg or oliguria)
at 24 H after admission
• Transferred from outside hospital
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
49. 49
Outcomes Statistical Test
• In-hospital mortality
• Extended GCS (GCS-E) on
discharge and 6- month post-
discharge follow-up
Background Lit. review Back to EG Future Studies
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
20% event
rate
210
patients
80% power
65% RR
reduction with
P < 0.05
• Chi-square or two-sided Fischer’s
exact test
• Student’s t-test or Mann-Whitney
Test
• Poisson regression model
• Adjusted incidence rate ratios
(Adj. IRRs)
50. 50
Background Lit. review Back to EG Future Studies
Intervention and Monitoring
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
Exclusions from further analysis:
BB+ HR < 50 BPM or SBP < 100 mmHg or refusal to continue 10-day treatment period
Treatment X 10 days
20 mg PO propranolol (BB) Placebo (BB-)
Randomization
Isolated Severe TBI patients
53. Conclusions
53
Routine use of beta blockers
Survival+
outcomes
24 hours
Severe
Isolated
TBI
Researchers
• Propranolol administered at 24 h after
admission in patients with a severe
isolated TBI associated with a significant
decrease in mortality
Background Lit. review Back to EG Future Studies
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
54. Strengths and Weaknesses
54
Background Lit. review Back to EG Future Studies
• Single center study
• Unblinded
• Low number of participants
enrolled
• Randomized study
• Evaluated longer
term outcomes
• Use of a regression
model to adjust for
covariates
• Good representation
of different disease
states and profile
similar to EG
Khalili H, et al. 2020 World J Surg. 2020 Jun;44(6):1844-1853. Accessed Aug 11, 2022
55. Summary: Pooling everything together
55
Background Lit. review Back to EG Future Studies
Trial Design Primary findings Limitations Anna’s LOE
(1-4)
Ley et al.
2018
Prospective
observational
Lower adjusted mortality
Propranolol > other BBs
Observational 4
Ammar
2018
Prospective
Randomized
Lower catecholamine
levels on day 7 w/
propranolol
Small n
Single-center
Large exclusion
3
Habib
2018
Prospective
randomized
Shorter duration of MV
with propranolol
Single-center
Unknown
mortality benefits
Older population
2
Khalil
2020
Prospective
Randomized
Significant decrease in
mortality
Single center
Open label
1
56. Patient EG
EG is a 19 year-old male with no significant past medical history who is
brought to Lutheran General Hospital (LGH) with multiple fractures and a
head injury after a high-speed motorcycle accident. Imaging revealed
intraparenchymal, ventricular and subdural hemorrhages on the left side as
well as multiple fractures. The patient underwent immediate interventions
and was admitted to the surgical intensive care unit (SICU).
Imaging
Initial
Interventions
• Seizing upon
arrival
• Hypotensive
• GCS: 5
Physical
Exam/Vitals
56
• Propranolol 40
mg QID
Beta Blocker
• Multiple
hemorrhages
• Scapular,
tibial, fibular
and sacral
fractures
• Intubation
• External
fixation of
tibial/fibular
fractures
• EVD
placement
Background Lit. review Back to EG Future Studies
57. Background Lit. review Back to EG Future Studies
EG’s propranolol course
7/22/2022
(Day 11)
7/25/2022
(Day14)
7/27/2022
(Day 16)
Propranolol
20 mg QID
Propranolol
40 mg QID
Propranolol
50 mg QID
Per NG tube
58. 58
Background Lit. review Back to EG Future Studies
Similar to trials Different than trials
• Types of head injury
• GCS score
• Propranolol given after
24 hours since admission
• Younger patient with no
comorbidities
• Patient treated in a
different center with
different practices
• In response to the attending, the evidence behind propranolol/beta
blocker use in PSH 2/2 TBI is mainly based on small single center
studies. Data in injuries similar to EG are promising, but more
studies are needed.
59. 59
Background Lit. review Back to EG Future Studies
• Conduct larger, multi-center sites
• Determine which patients will benefit
• Age
• Comorbidities
• Types of injuries
Future Studies
61. 61
1. Ley EJ, Leonard SD, Barmparas G, et al. Beta blockers in critically ill patients with traumatic brain injury: Results
from a multicenter, prospective, observational American Association for the Surgery of Trauma study. J Trauma Acute
Care Surg. 2018;84(2):234-244. doi:10.1097/TA.0000000000001747
2. Khalili H, Ahl R, Paydar S, et al. Beta-Blocker Therapy in Severe Traumatic Brain Injury: A Prospective
Randomized Controlled Trial. World J Surg. 2020;44(6):1844-1853. doi:10.1007/s00268-020-05391-8
3. Zheng RZ, Lei ZQ, Yang RZ, Huang GH, Zhang GM. Identification and Management of Paroxysmal Sympathetic
Hyperactivity After Traumatic Brain Injury. Front Neurol. 2020;11:81. doi:10.3389/fneur.2020.00081
4. Sakai K, Kitagawa T, Suzuki K, Toh K, Yamamoto J. Paroxysmal sympathetic hyperactivity following acute diffuse
brain swelling due to traumatic brain injury: a case report with good clinical outcome. Egypt J Neurosurg.
2022;37(1):7. doi:10.1186/s41984-022-00146-0
5. Habib T, Sabry A, El-Beheiry A, Ahmed I. Role of early propranolol in weaning from mechanical ventilator in
severe traumatic brain injury patients. Res Opin Anesth Intensive Care. 2018;5(1):15. doi:10.4103/roaic.roaic_58_17
6. Baguley IJ. The excitatory:inhibitory ratio model (EIR model): An integrative explanation of acute autonomic
overactivity syndromes. Med Hypotheses. 2008;70(1):26-35. doi:10.1016/j.mehy.2007.04.037
7. Ammar MA, Hussein NS. Using propranolol in traumatic brain injury to reduce sympathetic storm phenomenon: A
prospective randomized clinical trial. Saudi J Anaesth. 2018;12(4):514-520. doi:10.4103/sja.SJA_33_18
References
PSH is most commonly described after brain trauma but can also occur after nontraumatic forms of acute brain disease, including anoxic-ischemic coma after cardiac arrest and intracranial hemorrhage
However, findings from other studies have suggested that a diagnosis of PSH in TBI patients was associated with longer hospitalization periods—approximately added at least 14 days—and worse clinical outcome had significantly lower motor scores and worse Glasgow Outcome Scale scores. The cause of increased mortality of PSH in severe TBI patients may result from those who did not respond to treatments rather than the complication itself, which leads to a prolonged duration of this complication, resulting in metabolic disorders or malnutrition and the deterioration of neurological condition occurring eventually
Furthermore, this model explains why those with less brainstem involvement have a shorter duration of paroxysm and a much easier recovery of upper-spinal inhibition.
Although consensus on the isolated symptoms of this complication consists of six core sympathetic and motor features (tachycardia, tachypnea, hypertension, hyperthermia, hyperhidrosis, and posturing), PSH is a complex syndrome that shows individual differences across a spectrum of clinical symptoms (1, 9, 16). In fact, few patients present with all symptoms, while the vast majority of patients present with a single combination or various combinations of core symptoms (11). This is partly because individual differences or some symptoms are masked by the TBI therapeutic process (e.g., analgesic and sedative)
The majority of patients will recover in a few weeks, while fewer severe cases remain in a low-response state of rehabilitation for several weeks to months, even more than 1 year after injury (6, 7, 9). With the time window of each episode being within a few minutes to 2 h, duration is influenced by individual differences and management measures (9, 11, 16, 48). A previous study of PSH in the ICU suggested that the average episode duration was about half an hour (9). With reference to the daily self-limitation of PSH, researchers found that the average frequency of episodes is about 5.8 times a day, through collection of qualitative data from different literature (9, 38). Episode severity is reduced with the duration of disease, and the natural course (from initial injury to the asymptomatic phase) of PSH is about 2 weeks in general (6, 49). To our knowledge, several features, such as sweating (the commonest), tachycardia, and posturing will continue to the rehabilitation stage of TBI
However, some limitations affect the identification of PSH in TBI patients. First, the isolated feature of PSH may be hidden in many TBI-related complications such as seizures, sepsis, hypoxia, hypoglycemia, and traumatic pain. Second, some diagnostic criteria are only suitable for use after special clinical features first appear
For instance, the key step in treatment of PSH patients with hyperhidrosis is sufficient fluid replacement, rather than control of the sympathetic outbreak, because dehydration will reduce consciousness, and either positive pharmacotherapy or external cooling is critical for hyperthermia, as fever is inherently harmful. Prompt and adequate treatment of PSH may reduce the likelihood of secondary complications, such as dehydration, weight loss and malnutrition, and muscle contractures.
Previous experience holds that there is a sympathetic positive feedback loop in patients with long-term duration that is impossible to disrupt, making treatment all the more difficult (67). Last, it is important to consider the optimal choices in terms of timing, route, and cycle of treatment (65, 68). Here, we classify treatment methods into two main types, pharmacologic and non-pharmacologic.
US, canda, Australia, n
cite
Patients receiving first BB dose > 30 days after admission placed in the BB- group
Blunt: does not include penetration
Patients receiving first BB dose > 30 days after admission placed in the BB- group
Change to another format
US, canda, Australia, n
cite
The AIS classifies individual injuries by body region as follows:
AIS 1 – Minor
AIS 2 – Moderate
AIS 3 – Serious
AIS 4 – Severe
AIS 5 – Critical
AIS 6 – Maximal (currently untreatable)
* 18-36 months after dx
* 18-36 months after dx
All fully reversible
Change to another format
US, canda, Australia, n
cite
* 18-36 months after dx
* 18-36 months after dx
All fully reversible
Change to another format
US, canda, Australia, n
cite
Association between beta-blocker therapy and in-hospital
survival, GOS-E at discharge and at 6 months were
evaluated using Poisson regression models with robust
standard errors. Potential confounding was adjusted for by
including the following covariates in the model: age, sex,
hypertension, diabetes mellitus, CVD, GCS, head AIS, ISS,
type of intracranial injury/injuries and neurosurgical
intervention. Results are reported as adjusted incidence rate
ratios (IRRs) with corresponding 95% confidence intervals
(CI). A two-sided p value of less than 0.05 was considered
statistically significant